Corey Logan, Ruterbusch Julie, Shore Ron, Ayoola-Adeola Martins, Baracy Michael, Vezina Alex, Winer Ira
Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United States.
Department of OB/GYN, Detroit Medical Center Graduate Medical Education, Detroit, MI, United States.
Front Oncol. 2022 Mar 23;12:842441. doi: 10.3389/fonc.2022.842441. eCollection 2022.
To evaluate risk of a second cancer and associated survival times in United States women with diagnosis of cancer.
The Surveillance Epidemiology and End Results (SEER) database was queried for 2 cohorts of women aged 18 - 89 with either an index gynecologic or non-gynecologic cancer diagnosed between 1992 - 2017. Index cases were followed to determine if a second primary cancer was subsequently diagnosed; defined according to SEER multiple primary and histology coding rules. Standard Incident Ratios (SIR) and latency intervals between index diagnosis and second primary diagnosis were evaluated. Among those who developed a second primary cancer, median survival times from diagnosis of second primary cancer were also calculated.
Between 1992 - 2017, 227,313 US women were diagnosed with an index gynecological cancer and 1,483,016 were diagnosed with an index non-gynecologic cancer. Among patients with index gynecologic cancer, 7.78% developed a non-gynecologic subsequent primary cancer. The risk of developing any non-gynecologic cancer following an index gynecologic cancer was higher than the risk in the general population (SIR 1.05, 95% CI 1.04 - 1.07). Organs especially at risk were Thyroid (SIR 1.45), Colon and Rectum (SIR 1.23), and Urinary System (SIR 1.33). Among women diagnosed with an index non-gynecologic cancer, 0.99% were diagnosed with a subsequent gynecologic cancer. The risk of developing a gynecologic cancer following a non-gynecologic cancer was also elevated compared to the average risk of the general population (SIR 1.05, 1.03 - 1.07), with uterine cancer having the highest SIR of 1.13.
The risk of a developing a second primary cancer and the corresponding survival time is based on the order and site of the index and subsequent cancer. Surveillance guidelines should be examined further to optimize survivorship programs.
评估美国已确诊癌症的女性患第二种癌症的风险及相关生存时间。
在监测、流行病学和最终结果(SEER)数据库中查询了1992年至2017年间确诊患有原发性妇科或非妇科癌症的18至89岁女性的两个队列。对索引病例进行随访,以确定随后是否诊断出第二种原发性癌症;根据SEER多种原发性和组织学编码规则进行定义。评估了标准发病比(SIR)以及索引诊断与第二种原发性诊断之间的潜伏期。在那些患第二种原发性癌症的患者中,还计算了从第二种原发性癌症诊断开始的中位生存时间。
1992年至2017年间,227,313名美国女性被诊断患有原发性妇科癌症,1,483,016名被诊断患有原发性非妇科癌症。在患有原发性妇科癌症的患者中,7.78%发展为非妇科后续原发性癌症。原发性妇科癌症后发生任何非妇科癌症的风险高于一般人群(SIR 1.05,95% CI 1.04 - 1.07)。特别有风险的器官是甲状腺(SIR 1.45)、结肠和直肠(SIR 1.23)以及泌尿系统(SIR 1.33)。在被诊断患有原发性非妇科癌症的女性中,0.99%被诊断患有后续妇科癌症。与一般人群的平均风险相比,非妇科癌症后发生妇科癌症的风险也有所升高(SIR 1.05,1.03 - 1.07),子宫癌的SIR最高,为1.13。
发生第二种原发性癌症的风险及相应的生存时间取决于索引癌症和后续癌症的顺序及部位。应进一步检查监测指南,以优化生存计划。